Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

Statistically-Significant Improvements in Measures of Cardiac and Upper Limb Function in Patients Treated with CAP-1002
Capricor to Seek Breakthrough Therapy or Regenerative Medicine Advanced Therapy Designation
Conference Call and Webcast to be Held Today at 8:00 a.m. Eastern Time
LOS ANGELES, April 25, 2017 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced positive top-line results from a safety and exploratory efficacy analysis of six-month data from the randomized 12-month Phase I/II HOPE Clinical Trial of CAP-1002 (allogeneic cardiosphere-derived cells), an investigational candidate for the treatment of patients with Duchenne muscular dystrophy, or DMD. Duchenne muscular dystrophy is a rare, life-threatening genetic disorder for which treatment options are limited.
Read more: Capricor Therapeutics ( CAPR )

BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

- Composition of Matter Patent with Expiration Date in 2034 -
LAVAL, QC, April 24, 2017  - BELLUS Health (TSX:BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that the U.S. Patent and Trademark Office has issued U.S Patent. No. 9,598,409, which grants claims covering the composition of matter of BELLUS' lead drug candidate, BLU-5937, and related imidazopyridine compounds, in addition to pharmaceutical compositions comprising BLU-5937 and uses thereof. The patent has an expiration date of 2034, excluding any potential patent term extension. Patent applications with similarly broad claims are currently pending in Europe, Japan, China and other industrialized nations.
Read more: BELLUS Health ( BLU )

CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)

Global Phase 3 Clinical Trial Results Selected for Oral Presentation
LOS ANGELES, April 21, 2017 -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators' choice in patients with relapsed and refractory soft tissue sarcomas (STS) has been selected for an oral presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. 
Read more: CytRx Corporation ( CYTR )

Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene ® in Latin America

NEW YORK, April 20, 2017 -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or "Immune Pharma") announced today that it has entered into a letter of intent with Pint Pharma GmnH, a pharmaceutical company focused on Latin America and other markets ("Pint"), which binds the parties to seek agreement regarding an exclusive license by Pint of the rights to commercialize Ceplene throughout Latin America, including Argentina, Brazil, Chile, Colombia and Mexico. Immune and Pint target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American countries based on the existing European marketing authorization and will carry out the full commercialization of the licensed product in the territory, including Ceplene registration, pricing and reimbursement, and sales and marketing activities.
Read more: Immune Pharmaceuticals ( IMNP )

CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

- Development Program Can Support Approval, No New Studies Requested
- NDA Submission by CytRx Being Prepared
- Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT
LOS ANGELES, April 19, 2017 -- CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS). STS remains a high unmet medical need.
Read more: CytRx Corporation ( CYTR )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker